|
|
|||
|
|||
|
|
|||
|
metvix |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
metvix Generic Name: methyl aminolevulinate Company: PhotoCure Date of Approval: July 28, 2004 Treatment for: Actinic Keratosis The U.S metvix. Food and Drug Administration (FDA) has approved methyl aminolevulinate,presently called Metvix, for photodynamic treatment of actinic keratosis (sun-induced,pre-cancerous skin condition). Approval to market the product in the United States is contingent on FDA's acceptanceof a tradename other than Metvix, which is expected in several weeks metvix. The Metvixtradename cannot be used due to similarity of an already existing tradename foranother dermatology product metvix. Metvix works in combination with the CureLight lamp, PhotoCure's light sourceused in the clinical trials. The novel, non-invasive treatment offered by Metvix for pre-cancerous skinconditions combines the local application of cream (Metvix), selectively absorbedinto abnormal cells, and illumination with a proprietary red light source (CureLight/Aktilite)to activate the drug. Metvix is approved for pre-cancerous skin lesions (actinic keratosis, AK) andnon-melanoma skin cancer (basal cell carcinoma, BCC) in most European countries,New Zealand and Australia, and for AK in the US. Actinic keratosis (AK), also called 'sun spots', is the most commonly diagnosedpre-cancerous skin condition metvix. Worldwide, it is estimated that about 20 millioncases of AK occur each year metvix. Early and effective treatment of AK is importantas, if left untreated, a certain number of these lesions may progress to squamouscell carcinoma, an aggressive and potentially life-threatening type of skincancer. |
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| mmetvix meetvix mettvix metvvix metviix metvixx etvix mtvix mevix metix metvx metvi m etvix me tvix met vix metv ix metvi x metvix emtvix mtevix mevtix metivx metvxi ametvix themetvix metvix | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
